The Smartest Dividend Stocks to Buy With $5,700 Right Now
High interest rates have weighed on Realty Income, making the stock a high-yield bargain.
Hormel Foods is poised to continue building on decades of steady performance.
Booking Holdings is new to the dividend landscape, but it won't stay under the radar for long.
10 stocks we like better than Realty Income ›
Buying stocks is especially fun when you're a dividend investor. Every share means more annual dividend income for your portfolio.
Any time you can buy a dividend stock for less than you believe it's worth, that's a smart buy. It's subjective, but there are several dividend stocks in the market right now, sitting at compelling prices that make sense for long-term investors.
Here are three examples. Even if you don't have $5,700 to spend, it's not a big deal since most brokerage accounts allow you to purchase fractional shares these days.
Realty Income (NYSE: O) is one of the best real estate investment trusts (REITs) that you'll come across. The company invests in and leases commercial real estate. Since REITs must pay out at least 90% of their taxable income to shareholders as dividends, they are naturally excellent dividend stocks. Realty Income yields a juicy 5.75% at its current share price, and pays a monthly dividend, something not many companies do.
But what makes Realty Income such a good business? Look to its rock-solid fundamentals, including a diverse real estate portfolio, net lease model, and investment-grade balance sheet. The company has managed to raise its dividend for more than 30 consecutive years, despite enduring some of the worst hardships the real estate market has faced, including the COVID-19 pandemic and the 2007-2009 financial crisis.
However, the stock is down 29% from its all-time high. Realty Income often uses debt to acquire new properties and grow. Interest rates have continued to rise, which can raise borrowing costs, slow growth, and, consequently, weigh on Realty Income's share price. Trading at just 14 times its funds from operations, Realty Income is a bargain that will likely continue to pay you increasingly more over time.
Hormel Foods (NYSE: HRL) offers consistency that few companies can. The Dividend King has increased its payout for 59 consecutive years and has paid dividends for nearly a century without fail. Most known for its Spam brand of canned meat, Hormel owns a portfolio of food and snack brands, including Spam, Jennie-O, Dinty Moore, Applegate, Planters, and Skippy. The stock's 3.8% dividend yield establishes a solid floor for annual investment returns.
Plus, you don't grow for generations by accident; the company has demonstrated its ability to adapt to changing consumer tastes and needs over the years. It has launched and acquired brands to shift its portfolio into growing categories, such as healthy and high-protein offerings, as well as snacks. Management aims to grow Hormel's net sales by an average of 2% to 3% annually and operating profits by 5% to 7% annually over the long term.
Investors can feel good about the dividend's safety. The payout ratio is manageable at 72% of 2025 earnings estimates, backed by an investment-grade balance sheet. The stock currently trades at 19 times estimated 2025 earnings, a reasonable valuation for a stock with Hormel's combination of dividend yield and resilient mid-single-digit earnings growth.
Booking Holdings (NASDAQ: BKNG) is the budget buster on this list with a recent share price around $5,600. But remember, many brokerages allow you to buy fractional shares, so don't pass on this emerging dividend rockstar because of its share price.
The company has become a global technology leader in the hospitality and travel industries, with its five primary brands: Booking.com, Priceline, agoda, Kayak, and OpenTable.
The stock only began paying a dividend last year, so it may not be on the radar for most dividend investors. That could soon change. Booking Holdings comes packed with dividend growth potential. Its payout ratio is just 18% of the company's 2025 earnings estimates, and analysts expect earnings to grow by an average of 15% annually over the next three to five years. The dividend could grow by leaps and bounds for quite a while.
Despite trading near its all-time highs, Booking Holdings offers value at its price. The stock trades at 26 times its 2025 earnings estimates, an attractive valuation given the anticipated mid-teens earnings growth and numerous years of dividend increases ahead. Investors who buy now should see their yield on cost skyrocket from its current 0.7% starting point. Booking Holdings' one-two punch of dividends and capital gains upside makes it a brilliant buy right now.
Before you buy stock in Realty Income, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Realty Income wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!*
Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Booking Holdings and Realty Income. The Motley Fool has a disclosure policy.
The Smartest Dividend Stocks to Buy With $5,700 Right Now was originally published by The Motley Fool
Fehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Footwear Firms Rejiggering Supply Chains Will See Long-Term Benefits
The threat of higher tariffs may have provided footwear firms with an unintended benefit as they took charge of rethinking their supply chains. That's because U.S. President Donald Trump's return to office for his second non-consecutive term had a built-in expectation that he would make good on his promise to raise tariff rates again. More from WWD Knitwear Brand PH5 Collaborates With Charles & Keith on Capsule Collection The Top Men's Shoe Collections From Pitti Uomo's Spring 2026 Edition May Swiss Watch Exports Slump After U.S. Tariff-led Surge And raise them he did. But this time, footwear firms were better prepared. The footwear industry was under siege in the aftermath of COVID, with shipments on pause amid ongoing supply chain issues. With Chinese production costs rising, some firms were already in the midst of strategizing where else to go even before Trump raised the duty rate on imports from China during his first term back in 2019. But the nature of producing footwear meant moving production to other locations was likely a multi-year process. In the years since COVID, production remains largely in China, although Vietnamese factories had become the go-to place for the manufacture of athletic performance shoes. Indonesia, India and Cambodia are now also growing their footwear production base, as is Mexico and other Latin American countries. Firms in the footwear sector began to move more aggressively their production to other locations outside of China once Trump won re-election in November. And they moved with quick speed to get ahead of any tariff increases. At Wolverine World Wide, less than 10 percent of products are expected to be sourced from China in 2025, down from the mid-teens earlier this year, as the company targets 'near zero' by 2026. Steve Madden Ltd. in May said it had already moved nearly all fall '25 shoe production for its core brands out of China, ahead of its prior mid-teens target for fall '25 and mid single-digits in spring '26. Crocs Inc. CEO Andrew Rees has expressed concern about Vietnam, where its sourcing for the U.S. market is at 47 percent. Vietnam is set to continue with the next round of trade talks with the U.S. later this month. In April, Trump unveiled his plan for global reciprocal tariffs, a move to get countries to re-negotiate their trade agreements with the U.S. Most of those tariffs are on pause through July 9, with the tariff rate set at a temporary 10 percent increase. The exception is China, which saw subsequent increases on some goods as high as 145 percent, but that's now on hold through mid-August as the U.S. and China fine-tune a framework for an agreement that would see duties rise to 55 percent from its current pause rate of 30 percent. Regardless of which trade agreements actually get done, the rethinking of footwear supply chains is expected to be beneficial for down the road. That's true whether tariffs go up or remain the same. And while higher duties impact corporate profits, not to mention higher costs to consumers, moving production to multiple locations allows for better flexibility in keeping goods closer to where they are needed. That's because supply chain 'disruptions are here to stay,' according to Venky Ramesh, AlixPartners' trade and tariff war room expert, who was part of a webinar hosted by AlixPartners. He also spoke about the need for firms to map sourcing and supply chain exposure as well as scenario planning so they can make informed decisions. Other participants also spoke about investing in trade law knowledge, logistics and operations, as well as looking at production components to see if different classifications are possible that could result in lower tariff rates. Best of WWD All the Retailers That Nike Left and Then Went Back Mikey Madison's Elegant Red Carpet Shoe Style [PHOTOS] Julia Fox's Sleekest and Boldest Shoe Looks Over the Years [Photos] Sign in to access your portfolio
Yahoo
38 minutes ago
- Yahoo
Retail Traders Just Sent This AI Health Stock Soaring 60%
Oscar Health (NYSE:OSCR) has exploded nearly 60% this week, adding close to $2 billion in market cap without a single press release or earnings update. The real catalyst? A retail trading frenzy. OSCR became one of the most-mentioned names on r/WallStreetBets, and trading volume followed suitnearly 50 million shares changed hands on Wednesday alone, the second-highest in the company's history. Options activity lit up as well, with call volumes hitting a record 152,414 that day, and another 95,000 contracts moving by Friday morning, nearly triple the norm. Beneath the surge is a company with serious revenue momentumup 48% in 2023 and 57% in 2024. Adjusted earnings per share reached $0.92 in Q1 2025. But Oscar isn't just selling insuranceit's selling a story. Management brands the company as a health-tech platform, powered by AI and run on what it calls a continuous hackathon model. That pitch, familiar to anyone who's followed high-multiple tech names, is likely helping Oscar catch a more generous valuation than traditional insurers. Retail traders appear to be buying into that promise. Another factor? The Kushner connection. Joshua Kushner, vice chairman of Oscar's board and brother to Jared Kushner, has remained a prominent name in business and politics alike. That visibility might be adding an extra layer of speculation to the mix. But for now, the stock's movement is being driven more by momentum than fundamentals. Oscar is just $3 shy of its all-time highand the retail crowd seems determined to carry it the rest of the way. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ('AIM' or the 'Company') (NYSE American: AIM) today announced the receipt of a warning notification (the 'Letter') from the NYSE American LLC (the 'NYSE American') stating that the Company is not in compliance with the minimum stockholders' equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the 'Company Guide') requiring stockholders' equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders' deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024. The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025, when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025. On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The Company's common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol 'AIM'. The Letter in no way has any effect on such trading and does not affect the Company's business, operations or reporting requirements with the U.S. Securities and Exchange Commission. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company's intention to regain compliance with the listing requirements of the NYSE American and its ability to do so. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date hereof, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, subsequent events or otherwise, except as required by law. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@ in to access your portfolio
